On October 17-19, 2021, the American Neurological Association will host its second interactive, virtual meeting experience.
Our Head of Translational Medicine Dr Ryan Schubert will present "ASN51, an Orally Bioavailable Small-molecule O-Glcnacase Inhibitor, Has Both Immediate and Disease-modifying Benefits in Preclinical Models of Parkinson’s Disease and Epilepsy" at the poster tour session "Movement Disorders 2" on October 18, 2021 at 6:30 PM ET.
ANA2021 is considered the top meeting for academic neurologists and neuroscientists at every career stage, offering the opportunity to connect over groundbreaking research and best practices for success in the field.
Further information about the event
Further information about the programme